DZ3141A1 - Inhibiteurs d'aminotransferase acides aminés-dépendante à chaîne ramifiée, et leur utilisation dans le cadre du traitement de la rétinopathie diabétique. - Google Patents

Inhibiteurs d'aminotransferase acides aminés-dépendante à chaîne ramifiée, et leur utilisation dans le cadre du traitement de la rétinopathie diabétique.

Info

Publication number
DZ3141A1
DZ3141A1 DZ003141A DZ003141A DZ3141A1 DZ 3141 A1 DZ3141 A1 DZ 3141A1 DZ 003141 A DZ003141 A DZ 003141A DZ 003141 A DZ003141 A DZ 003141A DZ 3141 A1 DZ3141 A1 DZ 3141A1
Authority
DZ
Algeria
Prior art keywords
treatment
amino acid
branched chain
diabetic retinopathy
chain amino
Prior art date
Application number
DZ003141A
Other languages
English (en)
French (fr)
Inventor
Justin Stephen Bryans
Lain-Yen Hu
Susan M Hutson
Kathryn LANOUE
Lieth Erich Foley
Michael Francis Rafferty
Todd Robert Ryder
Ti-Zhi Su
Devin Franklin Welty
David Juergen Wustrow
Original Assignee
Warner Lambert Co
Penn State Res Found
Univ Wake Forest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Penn State Res Found, Univ Wake Forest filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DZ3141A1 publication Critical patent/DZ3141A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DZ003141A 1999-12-08 2000-11-08 Inhibiteurs d'aminotransferase acides aminés-dépendante à chaîne ramifiée, et leur utilisation dans le cadre du traitement de la rétinopathie diabétique. DZ3141A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16963599P 1999-12-08 1999-12-08
US17539900P 2000-01-11 2000-01-11
US23002000P 2000-09-05 2000-09-05
PCT/US2000/030769 WO2001042191A1 (en) 1999-12-08 2000-11-08 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy

Publications (1)

Publication Number Publication Date
DZ3141A1 true DZ3141A1 (fr) 2001-01-14

Family

ID=27389690

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ003141A DZ3141A1 (fr) 1999-12-08 2000-11-08 Inhibiteurs d'aminotransferase acides aminés-dépendante à chaîne ramifiée, et leur utilisation dans le cadre du traitement de la rétinopathie diabétique.

Country Status (33)

Country Link
EP (1) EP1157000B1 (es)
JP (1) JP2003516379A (es)
KR (1) KR20010101811A (es)
CN (2) CN1170811C (es)
AP (1) AP2001002242A0 (es)
AR (1) AR037738A1 (es)
AT (1) ATE308510T1 (es)
AU (1) AU784553B2 (es)
BG (1) BG105875A (es)
BR (1) BR0008443A (es)
CA (1) CA2361647A1 (es)
CO (1) CO5280055A1 (es)
CZ (1) CZ20012758A3 (es)
DE (1) DE60023657T2 (es)
DZ (1) DZ3141A1 (es)
EA (1) EA006597B1 (es)
EE (1) EE200100416A (es)
ES (1) ES2252075T3 (es)
GE (1) GEP20043298B (es)
HK (1) HK1044933B (es)
HR (1) HRP20010581A2 (es)
HU (1) HUP0200570A3 (es)
IS (1) IS6033A (es)
MA (1) MA26777A1 (es)
MX (1) MXPA01008085A (es)
NO (1) NO20013844L (es)
OA (1) OA11759A (es)
PE (1) PE20010929A1 (es)
PL (1) PL349193A1 (es)
SK (1) SK11022001A3 (es)
UY (1) UY26474A1 (es)
WO (1) WO2001042191A1 (es)
YU (1) YU57401A (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2296956T5 (es) * 2001-06-11 2011-07-12 Xenoport, Inc. Profármacos de análogos de gaba, composiciones y sus usos.
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA02010231A (es) 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
MXPA02010430A (es) * 2001-11-27 2003-06-02 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
DE602004010135T2 (de) * 2004-09-20 2008-09-04 Kao Corp. Verfahren zur Herstellung von Lactonen und deren Verwendung als Geruchsstoffe
BRPI0517227B8 (pt) 2004-11-04 2021-05-25 Xenoport Inc comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
US8828665B2 (en) 2007-02-16 2014-09-09 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2008155619A2 (en) * 2007-06-21 2008-12-24 Pfizer Inc. Preparation of optically-active cyclic amino acids
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
EP2481801A1 (en) * 2011-01-28 2012-08-01 Deutsches Krebsforschungszentrum Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia
US10941109B2 (en) 2011-06-13 2021-03-09 Ergon Pharmaceuticals Llc Compositions and methods of treatment using a BCAT1 inhibitor
WO2012173987A2 (en) * 2011-06-13 2012-12-20 Ergon Pharmaceuticals Llc Methods of treatment using a bcat1 inhibitor
CN111635937B (zh) * 2020-06-29 2021-10-08 江苏省中医院 Ass1或bckdk抑制剂在制备治疗溃疡性结肠炎的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0888286B1 (en) * 1996-03-14 2001-10-31 Warner-Lambert Company Novel substituted cyclic amino acids as pharmaceutical agents

Also Published As

Publication number Publication date
NO20013844L (no) 2001-10-04
DE60023657D1 (de) 2005-12-08
BG105875A (en) 2002-05-31
GEP20043298B (en) 2004-03-10
EA200100791A1 (ru) 2002-04-25
UY26474A1 (es) 2001-01-31
IS6033A (is) 2001-07-31
CZ20012758A3 (cs) 2002-09-11
AP2001002242A0 (en) 2001-09-30
KR20010101811A (ko) 2001-11-14
MXPA01008085A (es) 2002-04-24
NO20013844D0 (no) 2001-08-07
AR037738A1 (es) 2004-12-01
YU57401A (sh) 2004-05-12
HRP20010581A2 (en) 2002-08-31
EP1157000B1 (en) 2005-11-02
CN1626069A (zh) 2005-06-15
EP1157000A1 (en) 2001-11-28
ES2252075T3 (es) 2006-05-16
CO5280055A1 (es) 2003-05-30
HUP0200570A2 (en) 2002-06-29
PE20010929A1 (es) 2001-09-08
HK1044933B (zh) 2005-06-03
CN1170811C (zh) 2004-10-13
EA006597B1 (ru) 2006-02-24
DE60023657T2 (de) 2006-07-20
AU784553B2 (en) 2006-05-04
JP2003516379A (ja) 2003-05-13
AU1477901A (en) 2001-06-18
BR0008443A (pt) 2001-10-30
MA26777A1 (fr) 2004-12-20
CA2361647A1 (en) 2001-06-14
CN1344245A (zh) 2002-04-10
EE200100416A (et) 2002-12-16
SK11022001A3 (sk) 2002-11-06
HUP0200570A3 (en) 2003-02-28
WO2001042191A1 (en) 2001-06-14
PL349193A1 (en) 2002-07-01
HK1044933A1 (en) 2002-11-08
OA11759A (en) 2005-07-19
ATE308510T1 (de) 2005-11-15

Similar Documents

Publication Publication Date Title
DZ3141A1 (fr) Inhibiteurs d'aminotransferase acides aminés-dépendante à chaîne ramifiée, et leur utilisation dans le cadre du traitement de la rétinopathie diabétique.
CY2013032I2 (el) Συζυγη της εξενδινης-4 και η φαρμακευτικη τους χρηση
AR028426A1 (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero
PT1189895E (pt) Derivados de tiazole e oxazole e sua utilizacao farmaceutica
ATE318138T1 (de) Pharmazeutisches mittel zur behandlung von diabetes
DK1174135T3 (da) Farmaceutisk sammensætning omfattende pioglitazon og glimepirid til anvendelse i behandling af diabetes
DE69827518D1 (de) Medizinische flüssigkeitsinfusion und absaugen
BR9507999A (pt) Conjugado biologicamente ativo composto substancialmente purificado polimero solúvel em água e composição farmacêutica
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
DE69828895D1 (de) Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen
FR2774687B1 (fr) Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
EE05000B1 (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
DE60001735D1 (de) 1-aminotriazolo 4,3-a chinazolin-5-one und/oder -thione inhibitoren von phosphodiesterasen iv
EE200200214A (et) Dipüridamooli või mopidamooli kasutamine sellise ravimi valmistamiseks, mis on ette nähtud fibriinsõltuvate mikrotsirkulatsiooni häirete ennetamiseksja raviks
FR2760972B1 (fr) Utilisation de l-citrulline en medecine orthomoleculaire pour la vasoprotection, le tonus relaxatif des muscles lisses et la protection cellulaires
MA25391A1 (fr) Inhibiteurs d'alcenyl et alcynyl metalloproteases.
NO991581D0 (no) N-(benzotiazol-2-yl)piperidin-1-etanaminderivater, deres fremstilling og anvendelse i terapeutiske midler
DE60017383D1 (de) Selbstklebendes polymerisierbares monomer und damit hergestellte dental/medizinische zusammensetzungen
FR2795645B1 (fr) Nouvelle association pharmaceutique a activite analgesique
NO982942D0 (no) Blodforenlig og bakterieavvisende blokkopolymer
FR2826261B1 (fr) Composition a usage topique comprenant un produit cytotoxique et son utilisation dans le traitement de l'alopeche
DK0637956T3 (da) Anvendelse af remacemid til behandling af Parkinsonˆs sygdom
FR2807944B1 (fr) Utilisation de l'anethole-dithiolethione dans la prevention et le traitement de la tenotoxicite induite par un medicament
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
DE69732974D1 (de) 5-phenyl-3-pyridazinon-derivate und diese enthaltende arzneimittelzubereitungen